Baker Bros. Advisors’s Forma Therapeutics Holdings, Inc. Common Stock FMTX Stock Holding History

Baker Bros. Advisors’s Portfolio FMTX Stock Details FMTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,886,760	Closed	-$37.6M	–	127
2022 Q3	$37.6M	Sell	1,886,760 -138,116	-7%	-$1.82M	0.25%	30
2022 Q2	$14M	Hold	2,024,876	–	–	0.08%	58
2022 Q1	$18.8M	Hold	2,024,876	–	–	0.11%	53
2021 Q4	$28.8M	Hold	2,024,876	–	–	0.14%	48
2021 Q3	$47M	Hold	2,024,876	–	–	0.21%	41
2021 Q2	$50.4M	Hold	2,024,876	–	–	0.22%	37
2021 Q1	$56.7M	Hold	2,024,876	–	–	0.25%	34
2020 Q4	$70.7M	Buy	2,024,876 +253,367	+14%	+$11M	0.27%	25
2020 Q3	$88.3M	Sell	1,771,509 -228,491	-11%	-$9.23M	0.35%	19
2020 Q2	$93M	Buy	+2,000,000	New	+$86.7M	0.41%	19

Baker Bros. Advisors's FMTX Position: Q4 2022 in Review

Baker Bros. Advisors sold out of Forma Therapeutics Holdings, Inc. Common Stock (FMTX) in Q4 2022, closing a stake of 1,886,760 shares — an estimated $37.6M sold.

Baker Bros. Advisors first reported a position in FMTX in Q2 2020 and held it in 10 quarters. The position peaked at $93M in Q2 2020. 0 funds tracked by Wall St. Rank hold FMTX as of Q4 2022.

Baker Bros. Advisors reported no remaining Forma Therapeutics Holdings, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Baker Bros. Advisors sold 1,886,760 Forma Therapeutics Holdings, Inc. Common Stock shares in Q4 2022, an estimated $37.6M.
Baker Bros. Advisors first reported a position in Forma Therapeutics Holdings, Inc. Common Stock in Q2 2020 and held it in 10 quarters.
Baker Bros. Advisors's Forma Therapeutics Holdings, Inc. Common Stock position peaked at $93M in Q2 2020.
0 funds tracked by Wall St. Rank held Forma Therapeutics Holdings, Inc. Common Stock as of Q4 2022.

Based on Baker Bros. Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.